Transition of RSV Vaccine Ordering to NCIR
Effective Tuesday, October 21, 2025, the NCIP is transitioning RSV vaccine ordering from the Smartsheet Request Form to the North Carolina Immunization Registry (NCIR).
Immunization Provider Memos and Communications
The purpose of this memo is to provide important details regarding the upcoming holiday vaccine shipping schedule for the Vaccines for Children (VFC) and the 317 Vaccines for Adults (317 VFA) programs.
North Carolina Vaccines for Children (VFC) providers can now order the pentavalent meningococcal (A,B,C,W, and Y) vaccine, PENMENVY™ (NDC 58160-757-15) via NCIR for administration to their VFC-eligible adolescents (ages 10 through 18 years).
The purpose of this memo is to provide North Carolina Immunization Program (NCIP) providers with the latest information on the 2025-2026 COVID-19 vaccine. Please take time to carefully review this memo in full. COVID-19 vaccines for VFC-eligible patients are now available to order through NCIR.
This email is to inform you that the North Carolina Immunization Program (NCIP) has opened applications for birthing hospitals interested in participating in the replacement model for birth dose Hepatitis B and RSV.
The purpose of this email is to inform VFC-enrolled providers that the RSV monoclonal antibody product clesrovimab (trade name ENFLONSIA™ manufactured by Merck) is now available for ordering. VFC doses will begin shipping after Oct. 2, 2025.
Dear Local Health Department Partner,
Dear Providers,
On Wednesday, Aug. 27, 2025, FDA approved the updated 2025-2026 COVID-19 vaccines and rescinded Emergency Use Authorizations (EUA) for previously authorized COVID-19 vaccines.